3 Results for "

PSMA-negative cells

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "PSMA-negative cells" in MCE Product Catalog:

Cat. No.: HY-114256
CAS No.: 1610413-96-1
Target:  

PSMA

Research Areas:  

Cancer

EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to PSMA-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies .
loading...
    loading...
Cat. No.: HY-169336
CAS No.: 3024354-59-1
Target:  

PARP PSMA

Research Areas:  

Cancer

CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC50=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))
loading...
    loading...
Cat. No.: HY-181829
Target:  

EGFR PSMA LYTACs

Research Areas:  

Cancer

Ctx-L3 is a selective EGFR PTAC (PSMA-targeted chimera) degrader (DC50: 4.3 pM in LNCaP cells) and LYTAC. Ctx-L3 recruits prostate-specific membrane antigen (PSMA) and mediates lysosomal degradation of EGFR in PSMA-positive prostate cancer cells. Ctx-L3 exhibits degrading activity against EGFR in prostate cancer cells. Ctx-L3 is applicable to related research on prostate cancer .
loading...
    loading...